Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
10 2019
Historique:
received: 15 01 2019
revised: 01 05 2019
accepted: 28 05 2019
pubmed: 27 6 2019
medline: 1 7 2020
entrez: 26 6 2019
Statut: ppublish

Résumé

Determine whether adults with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk for disease- and steroid-related damage as compared to individuals with adult-onset SLE (aSLE), and whether they continue to accumulate disease damage in adulthood. Data derive from the 2007-2015 cycles of the Lupus Outcomes Study, a longitudinal cohort of adults with confirmed SLE. The Brief Index of Lupus Damage (BILD), a validated, patient-reported measure, was used to assess SLE-associated damage. Participants with baseline BILD were included (N = 1035). Diagnosis at age < 18 years was defined as cSLE (N = 113). Outcome variables included BILD score at baseline and follow-up, clinically significant change in BILD score over follow-up period, and presence of steroid-related damage (cataracts, osteoporosis-related fracture, avascular necrosis or diabetes mellitus). Mean time between baseline and follow up BILD assessment was 6.3 ± 1.7 years. In adjusted analyses, participants with cSLE and aSLE had similar levels of disease-related damage, and accumulated damage at similar rates. Participants with cSLE were more likely to report steroid-related damage (OR 1.7, 95% CI 1.1-2.8) in the adjusted analysis as compared to those with aSLE. Likelihood of steroid-related damage increased with disease duration for both groups, but was consistently higher among cSLE participants. In this longitudinal cohort of adults with SLE, participants continued to accumulate damage at similar rates over time, regardless of age at onset or disease duration. Childhood-onset predicted increased risk of steroid-related damage. Aggressive use of steroid-sparing treatment strategies during childhood may be important to prevent steroid-related damage in adulthood.

Identifiants

pubmed: 31235075
pii: S0049-0172(18)30763-7
doi: 10.1016/j.semarthrit.2019.05.010
pmc: PMC7480934
mid: NIHMS1622970
pii:
doi:

Substances chimiques

Glucocorticoids 0
Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-272

Subventions

Organisme : NIAMS NIH HHS
ID : K24 AR074534
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR070155
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635
pubmed: 28118527
Nat Rev Rheumatol. 2011 May;7(5):290-5
pubmed: 21487383
Arthritis Rheum. 2008 Feb;58(2):556-62
pubmed: 18240232
Arthritis Care Res (Hoboken). 2017 Feb;69(2):252-256
pubmed: 27214378
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1057-62
pubmed: 24376263
Arthritis Care Res (Hoboken). 2011 Aug;63(8):1170-7
pubmed: 21584946
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
J Rheumatol. 2003 Sep;30(9):1955-9
pubmed: 12966597
Rheumatol Int. 2016 Jul;36(7):955-60
pubmed: 26979603
Arthritis Rheum. 2012 Jul;64(7):2356-65
pubmed: 22294381
Arthritis Rheum. 2009 Jan 15;61(1):13-20
pubmed: 19116979
JAMA. 1960 Oct 22;174:966-71
pubmed: 13724595
Arthritis Rheum. 2007 Feb 15;57(1):56-63
pubmed: 17266065
Rheumatol Int. 2015 Apr;35(4):701-8
pubmed: 25257763
Arthritis Rheumatol. 2017 Aug;69(8):1612-1622
pubmed: 28480630
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
J Rheumatol. 2016 Jun;43(6):1050-6
pubmed: 27084911
Lupus. 2008 Apr;17(4):314-22
pubmed: 18413413
Arthritis Care Res (Hoboken). 2018 Jul;70(7):1101-1106
pubmed: 28973834

Auteurs

Merav Heshin-Bekenstein (M)

Division of Pediatric Rheumatology, University of California San Francisco. Address: 550 16th Street, 5th Floor, San Francisco, CA 94143-0632, United States; Pediatric Rheumatology Clinic, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv University, Israel. Electronic address: meravhb@tlvmc.gov.il.

Laura Trupin (L)

Rosalind Russell/Ephraim Engleman Rheumatology Research Center, University of California, San Francisco. Address: 513 Parnassus Avenue, Box 0500, United States.

Ed Yelin (E)

Rosalind Russell/Ephraim Engleman Rheumatology Research Center, University of California San Francisco. Address: UCSF San Francisco, CA 94143-0920, United States.

Emily von Scheven (E)

Division of Pediatric Rheumatology, University of California San Francisco. Address: 550 16th Street, 5th Floor, San Francisco, CA 94143-0632, United States.

Jinoos Yazdany (J)

Division of Rheumatology, University of California San Francisco, 1001 Potrero Avenue, Building 30, San Francisco, CA 94110, United States.

Erica F Lawson (EF)

Division of Pediatric Rheumatology, University of California San Francisco. Address: 550 16th Street, 5th Floor, San Francisco, CA 94143-0632, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH